Netherlands· NL-7e173eafe6d1
Paxneury 6 mg tabletten met verlengde afgifte
A guanfacine product containing guanfacinehydrochloride, registered in Netherlands by Neuraxpharm Pharmaceuticals S.L.. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Guanfacine is registered in 14 of 19 countries.
Countries holding a registration under ATC C02AC02 (guanfacine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Guanfacine · ATC C02AC02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of guanfacine costs, country by country.
Normalised to the WHO defined daily dose (3 mg), the median price runs from $0.21 in United States to $7.74 in Switzerland — a ×37 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Guanfacine · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$7.74
- US United States$0.21 (acquisition cost)
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- GUANFACINEHYDROCHLORIDE
- Manufacturer
- Neuraxpharm Pharmaceuticals S.L.
- Country
- Netherlands (NL)
- ATC code
- C02AC02
- ATC class
- Guanfacine
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1908
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
163 interactions on record for guanfacine.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Guanfacine · interactions on record
163 records
- 30 severe
- 133 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Guanfacine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomGuanfacine 6mg modified-release tabletsAlliance Healthcare (Distribution) Ltd
- CzechiaPAXNEURYNeuraxpharm Pharmaceuticals, S.L., Barcelona
- SpainPAXNEURY 6 MG COMPRIMIDOS DE LIBERACION PROLONGADANeuraxpharm Pharmaceuticals S.L.
- FinlandPaxneuryNeuraxpharm Pharmaceuticals S.L.
- IrelandPaxneury 6 mg prolonged-release tabletsNeuraxpharm Pharmaceuticals S.L.
- IcelandPaxneuryNeuraxpharm Pharmaceuticals S.L.
- NorwayPaxneuryNeuraxpharm Pharmaceuticals S.L.
- PolandPaxneuryNeuraxpharm Pharmaceuticals, S.L.
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Germany · Guanfacin Neuraxpharm
- United Kingdom (Northern Ireland) · Guanfacine Crescent
- Iceland · Intuniv, Paxneury
- Liechtenstein · Intuniv, Paxneury
- Norway · Intuniv, Paxneury
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/faa16de2-22e3-4c17-9ab0-f518d6bf0e2c GET /v1/drugs/faa16de2-22e3-4c17-9ab0-f518d6bf0e2c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet met verlengde afgifte",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/paxneury-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Guanfacine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132408",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"COPOLYMEER VAN ETHYLACRYLAAT-METHACRYLZUUR (1:1)",
"CROSPOVIDON (E 1202)",
"FUMAARZUUR (E 297)",
"GLYCEROLDIBEHENAAT",
"HYPROMELLOSE 2208 (Release controlling polymer), K4M (E 464)",
"LACTOSE 1-WATER",
"NATRIUMLAURILSULFAAT",
"POLYSORBAAT 80 (E 433)",
"POVIDON K 30 (E 1201)",
"SILICIUMDIOXIDE (E 551)"
],
"substances": [
"GUANFACINEHYDROCHLORIDE"
],
"leaflet_url": null,
"authorised_at": "2025/02/26",
"procedure_number": "EMEA/H/C/006312",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1908",
"additional_monitoring": "N"
}See everything about guanfacine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.